It’s action is to protect the brain cells affected by oxygen deprivation from destruction. The research team from the University of Queensland and Monash University has not yet conducted human trials. But Professor Glenn King, who led the research, said it showed “great promise” as a future treatment. “This world-first discovery will help us provide better outcomes for stroke survivors by limiting the brain damage and disability caused by this devastating injury,” he said. “”During preclinical studies, we found that a single dose of Hi1a administered up to eight hours after stroke protected brain tissue and drastically improved neurological performance,” the researcher added. Dr Kate Holmes, deputy director for research at the Stroke Association, said however it is unknown whether the protein could be used in treatments for humans in the future.